Biomnis, Genoma, and the Center for Human Genetics and Laboratory Diagnostics Martinsried, Enter Agreements with Illumina to

  Biomnis, Genoma, and the Center for Human Genetics and Laboratory
  Diagnostics Martinsried, Enter Agreements with Illumina to Expand Access for
  Non-Invasive Prenatal Testing Across Europe

Business Wire

SAN DIEGO -- June 30, 2014

Illumina, Inc. (NASDAQ:ILMN) today announced that it has entered into separate
agreements with Biomnis, Genoma, and the Center for Human Genetics and
Laboratory Diagnostics Martinsried, under which they will use the HiSeq 2500
and consumables from Illumina to develop and perform non-invasive prenatal
testing (NIPT). Biomnis plans to make NIPT available in France, Genoma plans
to perform NIPT services in Italy, and the Center for Human Genetics and
Laboratory Diagnostics will offer NIPT in Germany.

“Biomnis evaluated the different technologies and selected Illumina because of
their high level of performance as published in respected, peer-reviewed
medical journals,” said Dr. Charles Woler, CEO of Biomnis Laboratories.
“Backed by whole genome sequencing, we look forward to making our highly
accurate test accessible to physicians and their patients.”

“We are excited to offer NIPT through our network with the use of Illumina’s
technology,” said Dr. Francesco Fiorentino, CEO and Director of Genoma Group
Laboratories. “After evaluating different offerings, we selected Illumina’s
technology for its deep sequencing capabilities. We are continuously trying to
improve our service and offerings for patients and healthcare providers, and
we believe our physician customers and the expectant families they work with
will be thrilled to have access to this important information in an accurate,
safe, and efficient manner.”

“We decided on a partnership with Illumina because we share common values
regarding delivering high quality products and services,” said Dr. Hanns-Georg
Klein, CEO of the Center for Human Genetics and Laboratory Diagnostics
Martinsried. “One of the reasons we founded The Prenatalis Consortium was to
set standards and to further develop applications of NIPT in close cooperation
with leading prenatal centers in Germany. It is crucial to integrate NIPT into
the context of established prenatal diagnostics including ultrasound, invasive
prenatal diagnostics, and biochemistry.”

“These agreements are another step in establishing Illumina as a global leader
in reproductive and genetic health solutions and as a valued partner for
NGS-based testing across a broad range of clinical applications,” said Tristan
Orpin, Senior Vice President and General Manager of Reproductive and Genetic
Health for Illumina.

About Biomnis

Founded in 1897 by Marcel Mérieux, Biomnis is the leading provider of medical
laboratory testing services in France. With a menu of over 2,500 assays across
all biomedical disciplines, including specialised testing for which we have
all required authorisations, Biomnis performs over 40,000 tests per day for
more than 20,000 patients. Firmly rooted in pathology testing for over 100
years, Biomnis has become one of the largest providers of specialised medical
testing services both in France and internationally. Our growth is a result of
our ongoing innovation and technological investments, most notably in the
fields of female biology, oncology, personalised medicine, as well as
molecular and chromosomal genetics. For further information about the services
we provide please visit our website

About Genoma Group

GENOMA Group is a leading molecular genetics laboratory based in Italy,
internationally renowned as one of the largest, fully integrated, specialized
provider of state-of-the-art genetics testing services. Widely respected for
its excellence, innovation and deep scientific base, GENOMA is the center of
choice for groundbreaking genetic services worldwide. Since its inception in
1998, GENOMA Group offers private laboratories, public hospitals, physicians
and patients, a broad range of genetic tests, over 1.200 tests covering 18
different areas in the field of molecular diagnostics. For more information

About The Center for Human Genetics and Laboratory Diagnostics Martinsried

The Center for Human Genetics and Laboratory Diagnostics in Martinsried near
Munich was founded in 1998 as a spin-off from the Institute of Clinical
Chemistry at the University Hospital Grosshadern of the Ludwig-Maximilians
University. The facility is specialized in genetic and immunological
diagnostics. For more information visit


Illumina( is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this


Constance Lozet, +33 7 78 41 19 70
GENOMA Group - Molecular Genetics Laboratories
Dr. ssa Maura Menaglia, + 39068811270
Rebecca Chambers, 858-255-5243
Eric Endicott, 858-882-6822
Press spacebar to pause and continue. Press esc to stop.